Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.
NCT ID: NCT06305104
Last Updated: 2024-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
420 participants
INTERVENTIONAL
2023-07-18
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the first stage,180 healthy subjects, 140 tuberculosis（TB）subjects and 40 non-TB subjects with lung diseases aged 18 to 65 years old are divided into different groups through a randomized, blind methods. Every group carry out a low-dose (2.5μg/ml) or high-dose (5μg/ml) study, with 180 subjects in each dose group .Every subject injects intradermally EEC and EC randomly in both arms of the same person. Evaluate the consistency of assay results of EEC, EC and Interferon-Gamma Release Assay（IGRA）.Evaluate the sensitivity, specificity and consistency of assay results of EEC, EC and IGRA in healthy people, TB patients and non-TB patients with lung diseases, and determine the optimal dose of EEC for clinical auxiliary diagnosis of tuberculosis.
In the second stage, 60 healthy subjects and TB subjects aged 3-17 years and 66-75 years old are divided into different groups through a randomized, open, single-arm method with the target dose. Evaluate the safety, tolerance and preliminary efficacy of target dose of EEC in healthy people and TB patients aged 3 to 17 years old and 66 to 75 years old.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis
NCT06224608
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
NCT07152639
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
NCT05746611
A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried
NCT03026972
Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)
NCT02795260
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each subject's left and right arms will be randomly assigned to receive an intradermal injection of the experimental drug EEC and the control drug inoculated in both arms of the same person. A drug(EEC or EC) is injected in left arm first, observe 30 min and if no obvious adverse reaction ,then another drug (EEC or EC) will be injected in right arm. Observe and record the vital signs (breathing, heart rate, blood pressure ,temperature),the skin specific reaction (diameters of flush and induration of injection site) at 24h, 48h, 72h, 96h, and 7 days after skin test;local reactions (redness, pain, swelling, rash,itching) and a variety of adverse events. Evaluate the sensitivity , specificity and consistency rate of assay results of EEC, EC and IGRA in healthy subjects, TB patients and non-TB patients with lung diseases,determine the optimal dose of EEC for clinical auxiliary diagnosis of tuberculosis,and further evaluate the safety of EEC in healthy subjects, TB patients and non-TB patients with lung diseases.
In the second stage, 60 subjects aged 3-17 years old (30 cases) and 66-75 years old (30 cases) are enrolled, including 30 healthy subjects and 30 TB patients. Every subject is divided into different groups through a randomized, open label method, and receive a single intradermal injection of experimental drug (EEC) in one arm. Observe and record the vital signs (breathing, heart rate and temperature); laboratory examination and electrocardiogram (ECG) ;the skin specific reactions of injection site at 4h,8h,24h, 48h, 72h, 96h, and 7 days after skin test ; local reactions and a variety of adverse events，to further evaluate the safety and preliminary efficacy of EEC in people aged 3 to 75 years old.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TB subjects in 18-65 years old
140 TB subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
2.5μg/ml EEC
0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
5μg/ml EEC
0.1ml, one time, containing high dose 5μg/ml of active ingredients
5 unit（U） EC
0.1 ml , one time, containing 5U of active ingredients
healthy subjects in 18-65 years old
180 healthy subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
2.5μg/ml EEC
0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
5μg/ml EEC
0.1ml, one time, containing high dose 5μg/ml of active ingredients
5 unit（U） EC
0.1 ml , one time, containing 5U of active ingredients
non-TB subjects with lung disease in 18-65 years old
40 non-TB subjects with lung disease in 18-65 years old,each subject's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
2.5μg/ml EEC
0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
5μg/ml EEC
0.1ml, one time, containing high dose 5μg/ml of active ingredients
5 unit（U） EC
0.1 ml , one time, containing 5U of active ingredients
TB subjects in 3-17 years old and 66-75 years old
Each enrolled subject received a single intradermal injection of 0.1 ml of the test drug (EEC) in one arm; the Mantoux method was used to inject intradermally into the middle and lower 1/3 of the volar side of the forearm.
5μg/ml EEC
0.1ml, one time, containing high dose 5μg/ml of active ingredients
non-TB subjects in 3-17 years old and 66-75 years old
Each enrolled subject received a single intradermal injection of 0.1 ml of the test drug (EEC) in one arm; the Mantoux method was used to inject intradermally into the middle and lower 1/3 of the volar side of the forearm.
5μg/ml EEC
0.1ml, one time, containing high dose 5μg/ml of active ingredients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2.5μg/ml EEC
0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
5μg/ml EEC
0.1ml, one time, containing high dose 5μg/ml of active ingredients
5 unit（U） EC
0.1 ml , one time, containing 5U of active ingredients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. At the time of enrollment - For healthy subjects:enrollment is 3 \~ 75 years old (including 3 years old and 75 years old), regardless of gender ;
2. Guardians of persons aged 3-7 years , persons aged 8-17 years old and their guardians, persons aged 18-75 years old themselves and/or their guardians (spouse or children) agree to participate in this trial and sign an informed consent form;
3. The person and/or guardian can comply with the requirements of the clinical trial protocol to participate in /accompany the subject to follow- up visits;
4. After medical history inquiry, there is no history of tuberculosis (including intrapulmonary and external tuberculosis ) and close contact history with tuberculosis patients (referring to direct contact with registered tuberculosis patients from 3 months before diagnosis to 14 days after starting anti-tuberculosis treatment);
5. Those who have no clinical symptoms of tuberculosis poisoning and whose chest imaging examination (for subjects aged 15 to 75 years old) is normal or abnormal without clinical significance;
6. Normal or abnormal measurements of vital signs ( axillary temperature, pulse , respiration , blood pressure ) and electrocardiogram have no clinical significance; \[ The axillary temperature of all subjects was measured \< 37.3°C ; blood pressure was measured in subjects aged 18-75 years (systolic blood pressure \<160 millimetres of mercury（mmHg） and diastolic blood pressure \<100mmHg) ; pulse and respiration were determined by the researcher based on the subject's age\]
7. Physical examinations are normal or abnormal with no clinical significance;
8. Laboratory tests including blood routine, urine routine, and blood biochemistry tests were all normal or abnormal with no clinical significance.
* For patients with tuberculosis (including pulmonary tuberculosis):
1. Those who was diagnosed with tuberculosis/ pulmonary tuberculosis according to the "People's Republic of China Health Industry Standard Pulmonary Tuberculosis Diagnostic Criteria " combined with the "Technical Guidelines for Tuberculosis Prevention and Control in China ( 2021 Edition )" (accepted clinical comprehensive analysis diagnosis);
2. The age at the time of enrollment is 3 to 75 years old (including 3 years old and 75 years old), regardless of gender ;
3. Guardians of persons aged 3-7 years old, persons aged 8-17 years old and their guardians, persons aged 18-75 years old themselves and/ or their guardians (spouse or children) agree to participate in this trial and sign an informed consent form;
4. The person and /or guardian may comply with the requirements of the clinical trial protocol and participate in follow-up visits.
* For patients with non-tuberculous lung disease
1. Patients with clear clinical diagnosis of pulmonary disease, and the clinician can rule out pulmonary tuberculosis and extrapulmonary tuberculosis based on the patient's clinical manifestations, imaging and laboratory tests (including IGRA );
2. Age at the time of enrollment is 18 to 65 years old (including 18 years old and 65 years old), regardless of gender;
3. Those who agree to participate in this trial and sign the informed consent form;
4. Those who may comply with the requirements of the clinical trial protocol and participate in follow-up visits
Exclusion Criteria
* who have convulsions, epilepsy, a history of mental illness and / or a family history of mental illness (immediate relatives);
* People with allergies, such as those who have a history of allergies to two or more drugs or foods, or those who are known to be allergic to the components of this medicine;
* Those currently suffering from acute infectious diseases (such as measles, whooping cough, influenza, etc.), acute conjunctivitis, acute otitis media, and generalized skin diseases;
* After consultation, have a history of past or current serious heart, liver, kidney, digestive system, respiratory system, nervous system, mental disorder and metabolic disorders;
* Those who are currently suffering from acute febrile illness; or those who have used antipyretic, analgesic and anti-allergic drugs within 3 days before the skin test and which may affect the research evaluation as assessed by the researcher ;
* People with serious infections (such as pyoderma, severe eczema, etc.);
* who are participating in or participating in any other new drug clinical trials within 3 months;
* Have received non-live vaccines within 7 days before the skin test , or have received live attenuated vaccines within 28 days ;
* Lactating or pregnant women, or female subjects of childbearing age who have a positive pregnancy test before enrollment and who have not taken effective contraceptive measures 2 weeks before enrollment.
* Those with a history of drug abuse;
* Any other circumstances that the investigator believes may affect the evaluation of the study.
3 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Chest Hospital, Capital Medical University
OTHER
Wuhan Institute for Tuberculosis Control
OTHER
The Public Health Clinical Center of Chengdu
UNKNOWN
Xuzhou Infectious Disease Hospital
UNKNOWN
Jiangsu Province Centers for Disease Control and Prevention
NETWORK
Changde First People's Hospital
UNKNOWN
Chengdu CoenBiotech Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chest Hospital
Beijing, Beijing Municipality, China
Wuhan Institute for Tuberculosis Control
Wuhan, Hubei, China
Changde First People's Hospital
Changde, Hunan, China
Jiangsu Province Centers for Disease Control and Prevention
Nanjing, Jiangsu, China
Xuzhou Infectious Disease Hospital
Xuzhou, Jiangsu, China
Public health clinical center of chengdu
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KN-EEC-II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.